Clinical trials: Giant Cell Glioblastoma
Brain and Central Nervous System Tumors
Temozolomide Plus Carboplatin in Treating Patients With Recurrent Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00021307
- Testing
- carboplatin, temozolomide
- Sponsor
- Fox Chase Cancer Center
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
This phase I trial is studying the side effects and best dose of arsenic trioxide and radiation therapy in treating patients with newly diagnosed malignant glioma.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00045565
- Testing
- arsenic trioxide, radiation therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be effective in treating malignant glioma.
- Trial name
- NCT00036972
- Testing
- cintredekin besudotox, adjuvant therapy, conventional surgery
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
This phase II trial studies how well giving hypofractionated radiation therapy together with temozolomide and bevacizumab works in treating patients with high-grade glioblastoma multiforme or anaplastic glioma.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma
- Trial name
- NCT01478321
- Testing
- Temozolomide, hypofractionated radiation therapy, bevacizumab
- Where
- 5 sites in United States
- Volunteers
- 54 people
- Sponsor
- Northwestern University
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
This phase I/II trial is studying the side effects and best dose of cediranib to see how well it works when given together with temozolomide and radiation therapy in treating patients with newly diagnosed glioblastoma.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00662506
- Testing
- Cediranib Maleate, Diffusion Tensor Imaging, Diffusion Weighted Imaging
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Central Nervous System Neoplasm
Vaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme
RATIONALE: Vaccines made from a person's tumor cells and dendritic cells may help the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00890032
- Testing
- BTSC mRNA-loaded DCs
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- John Sampson
Brain and Central Nervous System Tumors
Pyrazoloacridine Followed by Radiation Therapy in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00006355
- Testing
- pyrazoloacridine, adjuvant therapy, radiation therapy
- Where
- 8 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
This phase I/II trial is studying the side effects and best dose of motexafin gadolinium when given together with temozolomide and radiation therapy and to see how well they work in treating patients with newly diagnosed…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00305864
- Testing
- 3-Dimensional Conformal Radiation Therapy, Motexafin Gadolinium, Temozolomide
- Where
- 106 sites in United States
- Volunteers
- 118 people
- Sponsor
- National Cancer Institute (NCI)
Giant Cell Glioblastoma, Recurrent Glioblastoma
Vaccine Therapy in Treating Patients With Recurrent Glioblastoma
This pilot early phase I trial studies the side effects of vaccine therapy in treating patients with glioblastoma that has come back.
- Conditions
- Giant Cell Glioblastoma, Recurrent Glioblastoma, Recurrent Gliosarcoma
- Trial name
- NCT03360708
- Testing
- Laboratory Biomarker Analysis, Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Brain and Central Nervous System Tumors
Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT01013285
- Testing
- bevacizumab, temozolomide, external beam radiation therapy
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Brain and Central Nervous System Tumors
Thalidomide and Irinotecan in Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation Therapy
RATIONALE: Thalidomide may stop the growth of glioblastoma multiforme by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00039468
- Testing
- irinotecan hydrochloride, thalidomide
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma
This phase I trial is studying the side effects and best dose of cediranib maleate when given together with cilengitide in treating patients with progressive or recurrent glioblastoma.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
- Trial name
- NCT00979862
- Testing
- Cediranib Maleate, Cilengitide, Laboratory Biomarker Analysis
- Where
- 11 sites in United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)